Dr. Stoelzel received his Ph.D. in Neuroscience from the University of Connecticut (2007). His current work focuses on how circadian rhythms and environmental experience dependent mechanisms such as diet can alter hypothalamic function at the neuronal level, and how that altered function contributes to the development of type 2 diabetes.
Creators of Cycloset®*, the first and only FDA approved sympatholytic dopamine D2 receptor agonist for the treatment of type 2 diabetes.
*See full prescribing info
